Better Survival in Refractory CRC With Chemo Plus Bevacizumab, Real-World Study Says

(MedPage Today) — Overall survival (OS) in refractory metastatic colorectal cancer (mCRC) improved significantly with the addition of the VEGF inhibitor bevacizumab (Avastin) to chemotherapy, data from a real-world analysis showed.
A propensity…